Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Conditions:   Adenoid Cystic Skin Carcinoma;   Adnexal Carcinoma;   Anaplastic Large Cell Lymphoma, ALK-Negative;   Anaplastic Large Cell Lymphoma, ALK-Positive;   Apocrine Carcinoma;   Cylindrocarcinoma;   Digital Papillary Adenocarcinoma;   Endocrine Mucin-Producing Sweat Gland Carcinoma;   Extramammary Paget Disease;   Extraocular Cutaneous Sebaceous Carcinoma;   Hidradenocarcinoma;   Keratoacanthoma;   Malignant Sweat Gland Neoplasm;   Merkel Cell Carcinoma;   Microcystic Adnexal Carcinoma;   NK-Cell Lymphoma, Unclassifiable;   Papillary Adenocarcinoma;   Porocarcinoma;   Primary Cutaneous Mucinous Carcinoma;   Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Recurrent T-Cell Non-Hodgkin Lymphoma;   Refractory Anaplastic Large Cell Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Refractory Merkel Cell Carcinoma;   Refractory Mycosis Fungoides;   Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Skin Squamous Cell Carcinoma;   Refractory T-Cell Non-Hodgkin Lymphoma;   Sezary Syndrome;   Signet Ring Cell Carcinoma;   Skin Basal Cell Carcinoma;   Skin Basosquamous Cell Carcinoma;   Skin Squamous Cell Carcinoma;   Spiradenocarcinoma;   Squamoid Eccrine Ductal Carcinoma;   Squamous Cell Carcinoma of Unknown Primary;   Sweat Gland Carcinoma;   Trichilemmal Carcinoma;   Vulvar Squamous Cell Carcinoma
Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: Talimogene Laherparepvec
Sponsor:   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 30, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments